Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety

Ekaete Olajide Alaje, Ekong Emmanuel Udoh, Patrick Aboh Akande, Friday Akwagiobe Odey, Martin Madu Meremikwu, Ekaete Olajide Alaje, Ekong Emmanuel Udoh, Patrick Aboh Akande, Friday Akwagiobe Odey, Martin Madu Meremikwu

Abstract

Introduction: fever is the primary symptom of most childhood illnesses and a cause of concern to their caregivers. The antipyretics commonly used to treat fever are ibuprofen and paracetamol. Most studies on the effectiveness of ibuprofen and paracetamol in treating fever in under-fives were conducted in Europe and North America with very few in African children. This study was aimed at assessing the effectiveness and safety of a single dose therapy of ibuprofen versus paracetamol for treating childhood fever in Nigeria.

Methods: a randomized, controlled clinical trial was conducted in the University of Calabar Teaching Hospital, in Nigeria. A total of 140 eligible children aged 6-59 months with tympanic temperature of 38°C-40°C were enrolled, and 70 of them were assigned to one arm that received a single dose of ibuprofen (10mg/kg) and 70 had paracetamol (15mg/kg). After drug administration, the children were admitted and observed in the hospital for six hours during which period a half-hourly temperature measurement and monitoring for adverse events were done.

Results: the overall result showed that ibuprofen had a better fever reducing effect compared to paracetamol. The proportion of afebrile children in the ibuprofen versus paracetamol group at 1.5-2.5 hours of administration of the drugs was statistically significant (p = 0.04). The adverse events of both drugs were mild and quite comparable with vomiting being the commonest.

Conclusion: ibuprofen is more effective in the treating fever in under-fives compared to paracetamol. The adverse events of both drugs were mild and comparable.

Keywords: Ibuprofen; effectiveness; fever; paracetamol; safety; trial; underfives.

Conflict of interest statement

The authors declare no competing interests.

Copyright: Ekaete Olajide Alaje et al.

Figures

Figure 1
Figure 1
clinical trial flow diagram
Figure 2
Figure 2
AUC for mean temperature reduction at different time points

References

    1. National Population Commission (NPC) [Nigeria] Abuja, Nigeria: NPC, NMCP, and ICF International. 2012. National Malaria Control Programme (NMCP) [Nigeria], and ICF International, Nigeria Malaria Indicator Survey 2010.
    1. Hay AD, Heron J, Ness A, the ALSPAC study team. The prevalence of symptoms and consultations in preschool children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. Fam Pract. 2005;22:367–74.
    1. WHO. World Health Organization, City. 2005. Handbook: Integrated Management of Childhood Illness, In Book Handbook, Integrated Management of Childhood Illness.
    1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375:1969–87.
    1. Meremikwu MM, Oyo-Ita A. Physical methods versus drug placebo or no treatment for managing fever in children. Cochrane Database of Systematic Reviews. 2003;2 doi: 10.1002/14651858.CD004264.. Art. No.: CD004264.
    1. World Health Organization. Geneva: World Health Organization; 2000. Integrated Management of Childhood Illness.
    1. Oshikoya KA, Senbanjo IO. Fever in children: Mothers’ perceptions and home management. Iran J Pediatr. 2008;18:229–36.
    1. Sneader W. Hoboken, NJ: Wiley; 2005. Drug Discovery: A History.
    1. Adams SS. The propionic acids: A personal perspective. J of clin pharmacol. 1992;32:317–23.
    1. Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of Acetaminophen vs Ibuprofen for treating children’s pain or fever: a meta-analysis. Arch Pediatr Adolesc Med. 2004;158:521–6.
    1. Goodman, Gilman’s . The Pharmacologic Basis of Therapeutics. In: Gilman AG, Rall TW, editors. 8th ed. New York, NY: Pergamon Press; 1990.
    1. Jennifer A, Kerry M, Yehudit P. Acetaminophen and Ibuprofen Over dosage. Paediatrics in Review. 2012;33:188.
    1. Federal Republic of Nigeria 2006, Population and Housing Census. National Population Commission, Abuja, Nigeria. April 2010.
    1. Suresh KP and Chandrashekara S. Sample size estimation and power analysis for clinical research studies. Journal of Human Reproductive Sciences. 2012;5(5 IP):41.190.2.154.
    1. Vyas FI, Rana DA, Patel PM, Patel VJ, Bhavsar RH. Randomized comparative trial of efficacy of paracetamol, ibuprofen and paracetamol-ibuprofen combination for treatment of febrile children. Perspect Clin Res. 2014;5:25–31.
    1. European Medicines Agency. Guideline for Good Clinical Practice. 2002:1–42. Accessed on July 2012.
    1. World Medical Association. Declaration of Helsinki. 6th revision. 2008. Accessed on 26 February 2009.
    1. El-Rahdi AS and Patel S. An evaluation of tympanic thermometry in a paediatric emergency department. Emerg Med J. 2006;23:40–1.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Trials. 2010;11:32.
    1. Seyfhashemi M, Ghorbani R, Mehralizadeh S, Asgarzadeh S, Bahadoran P. A comparison of the antipyretic effect of Acetaminophen and Ibuprofen in febrile children hospitalized at Amir-al-Momenin Hospital in Semnan (Iran) IJPT. 2007;6:213–5.
    1. Autret-Leca E, Gibb IA, Goulder MA. Ibuprofen versus Paracetamol in paediatric fever: objective and subjective findings from a randomized, blinded study. Curr Med Res Opin. 2007;23:2205–11.
    1. Hay AD, Redmond NM, Costelloe C, Montgomery AA, Fletcher M, Hollinghurst S, et al. Paracetamol and Ibuprofen for the treatment of fever in children: the PITCH randomized controlled trial. Health Technol Assess. 2009;13(27):iii–iv. ix–x, 1–163.
    1. Lesko SM, Mithell AA. The safety of acetaminophen and ibuprofen among children younger than two years old. Pediatrics. 1999;104:e39.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅